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Scleroderma is characterized by an excessive deposition of collagen in all involved organs. This is due to an
overproduction of extracellular matrix (ECM) molecules following induction of gene expression, whereas there is no
evidence that the composition of the connective tissue matrix is altered. Several in vivo studies and in vitro
experiments suggest that a close interaction between inflammatory cells and fibroblasts is required for the initial
activation of fibroblasts. TGF-beta presumably plays an important role, but other cytokines, e.g., PDGF or FGF, may also
be involved. Many of the ECMmolecules have been shown to interact closely with fibroblasts and provide signals that
regulate fibroblast metabolism. The cellular response towards those signals is a further aspect of fibrosis that has
attracted attention during recent years. The altered expression of receptor proteins on the cell surface of scleroderma
fibroblasts for example might explain in part the lack of down-regulation of collagen synthesis in late phases of the
disease. This review summarizes the alterations of connective tissue in scleroderma, and discusses the role of
cytokines as well as the ECM for the regulation of fibroblast function and their implication for the development of
fibrosis. J Invest Dermatol 100:92S–96S, 1993
Systemic scleroderma is a chronic disease involving many connective
tissue containing organs [1,2]. It is characterized by the development
of fibrosis due to an excessive deposition of connective tissue. The
underlying pathogenetic events are still not fully understood and several
mechanisms have been proposed and are being discussed [3]. These
include vascular alterations with microvascular endothelial cell damage,
an augmented autoimmune response and direct disturbances in the
control of connective tissue synthesis. Most likely, however, all three
systems are directly linked, and their close morphologic and functional
interaction determines the extent and localization of a fibrotic response.
Certainly the genetic background plays an important role, and several
groups of investigators have demonstrated an association of distinct
subsets of scleroderma patients with the major histocompatibility complex
[4–6]. In this review we will focus on the alterations of connective tissue
metabolism occurring in scleroderma and describe some of the molecular
mechanisms involved in these disturbances.
HISTOPATHOLOGY OF SCLERODERMA
Histologic alterations of scleroderma skin are not very characteristic. In
early lesions mild to moderate cellular infiltrates with lymphocytes,
monocytes, and histiocytes can be observed. They are usually located
around blood vessels in the deep dermis or the subcutaneous tissue.
Electronmicroscopy reveals thin, irregular collagen fibrils with a diameter
of 10 to 30 nm [7,8]. Also increased staining with antibodies directed
against procollagens I and III are reported to occur in the same area [8]. In
later stages the lympho-histiocytic infiltrates disappear and microscopic
alterations of connective tissue are visible. The collagen bundles are
thickened, closely packed, and stain eosinophilic. The sweat glands are
atrophic and become restricted to the papillary dermis. Vessels show
thickening of the walls [7–9].
These observations of morphologic alterations in connective tissue were
strengthened by in vitro and in vivo studies showing that enhanced
connective tissue synthesis in scleroderma is associated with increased
mRNA levels for collagen [10]. More recently, the application of in situ
hybridization techniques showed that high levels of collagen alpha1 (I)
mRNA were detected mainly in fibroblastic cells co-localizing with the
perivascular infiltrates (Fig 1) [11,12]. The close interaction of inflammatory
cells, endothelial cells, and activated fibroblasts indicated that mediators
released by the surrounding cell types might activate fibroblast metabolism.
Subsequently expression of TGF-beta was investigated by antibody staining
as well as by in situ hybridization [13,14]. Although some discrepant results
have been published, in some patients a close co-localization of TGF-beta2
mRNA with alpha, (I) mRNA levels could be detected (Fig 2). Until now, it
was not possible, however, to identify the cells responsible for TGF-beta2
expression, leaving both the inflammatory cells of the infiltrates as well as the
endothelial cells as candidates.
THE COMPOSITION OF THE ECM IN SCLERODERMA
The altered histologic appearance of the connective tissue in late phases
of scleroderma has prompted several studies to analyze the structural
components of the connective tissue matrix. The extracellular matrix is
composed of a large number of different collagenous and non-
collagenous molecules (Table I). An exact chemical analysis of the skin
is technically difficult and therefore revealed divergent results. In
scleroderma skin, alterations in the content of dermatan and chondroitin
sulfate as well as collagens I and III have been reported [15,16], whereas
different data were obtained using cell cultures. Nevertheless most studies
demonstrate an induction of collagen synthesis as shown by in situ
hybridization (see above), indirect immunofluorescence staining with
procollagen antibodies, or measuring prolylhydroxylase activity as a
maker of procollagen synthesis [17–19].
CIRCULATING TYPE III COLLAGEN AMINOPROPEPTIDE
LEVELS IN SERA OF PATIENTS WITH SCLERODERMA
Collagen is synthesized in a precursor form, procollagen, that is secreted
into the extracellular space where the N- and C-terminal procollagen
peptides are cleaved off by specific proteases [20]. The serum concentra-
tion of free aminopropeptides of type III collagen can be measured using a
radioimmunoassay. Several studies have been conducted to correlate
these levels with disease activity in fibrotic disorders [21]. Scleroderma
patients have also been studied and found to have increased levels of
circulating aminoterminal procollagen peptides (Table II). Furthermore,
increased levels were correlated with the degree of involvement of the
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skin and internal organs. In addition, when progression of the disease was
monitored there was a high correlation with the levels of aminopropep-
tides in serum, which were found to be strongly elevated in patients with a
rapid progression. These clinical studies together with the morphologic
investigations summarized above indicate that actually in vivo activation
of collagen synthesis is a main factor in the pathogenesis of the disease
and is closely related to the progression in individual patients [22–24].
FIBROBLAST CULTURES AS A MODEL SYSTEM FOR
STUDYING ALTERATIONS OF CONNECTIVE TISSUE
METABOLISM IN SCLERODERMA
For many years fibroblast cultures have been used to investigate
disturbances of connective tissue metabolism in scleroderma.
As early as 1971 Le Roy and colleagues could demonstrate enhanced
collagen production in some cell strains obtained from patients with
systemic scleroderma [25]. This was later substantiated by several other
investigators. Furthermore it became clear that overproduction of collagen
could only be detected in some cell strains and only in early subcultures
[26–29]. To a certain extent this phenomenon could be explained by a
selection of fibroblast populations. In the initial studies full-thickness
biopsies were used to initiate the cultures. Later, fibroblasts were grown
from different layers of the skin, and increased collagen synthesis was
observed mainly in fibroblasts grown from the deep reticular dermis of
patients in early stages of scleroderma [27]. These cell strains, however,
still lost their phenotype after several subcultures. This evidence for
different subpopulations of fibroblasts in scleroderma skin prompted
additional studies, and even in normal skin some demonstrated different
clones of fibroblasts characterized by a high or low synthesis of collagen.
In addition, when normal fibroblasts were grown in the presence of serum
obtained from scleroderma patients these activated sub-clones were
preferentially stimulated [30]. However, identification of these clones
in vivo is difficult and there are only few attempts to develop markers
recognizing distinct fibroblast sub-populations.
Nevertheless, some of the overproducing strains have been investi-
gated precisely in order to identify at which level dysregulation of
collagen metabolism takes place. Enhanced synthesis of collagen is
accompanied by an increase of prolyl and lysyl hydroxylase activity [31].
Both enzymes are essential for the post-translational modifications of the
collagen molecules, and their activity is usually closely linked to the
biosynthesis of collagen. In contrast, the activity of the sugar transferases,
the galactosyl and glucosyl transferases, were found not to be induced
[31]; still it remains unclear whether this could be relevant for the in vivo
situation resulting in altered glycosylation of newly synthesized collagen
molecules in scleroderma.
In other experiments, data obtained from an in vitro translation assay
demonstrated that enhanced synthesis of collagen correlates with
enhanced translation [32]. Northern and dot blot analysis as well as
nuclear run-off experiments using specific cDNA clones showed that
enhanced mRNA levels and enhanced transcription rates of collagen
Figure 1. Detection of collagen mRNA in scleroderma skin by in situ
hybridization. Labeling with alpha1(I) antisense RNA, 3 106 cpra/section.
Magnification  480. (Taken from [11].)
Figure 2. In situ hybridization of SSc skin with TGF-beta2 antisense probe.
Bright (a) and dark field (b) micrograph of frozen section of a biopsy from a
patient with the inflammatory stage of SSc. Magnification X216. (Taken from
[14].)
Table I. Composition of the Interstitial ECM in Skin
Collagens I, III, V Vitronectin
Collagen VI Elastin
Collagen XII, XIII, XIV Fibrillin
Proteoglycans Etc.
Fibronectin
Table II. Serum Levels of Type III Collagen
Aminopropeptides in Serum of Patients with Systemic
Scleroderma (SSc), Type I/II=1 SSc, Type III=dSSc
(taken from [29])
Patients P-III P (mg/ml) n
SSc total 74.5±24.6 191
SSc type I 58.8±20.5 61
SSc type II 70.9±26.7 78
SSc type III 96.1±38.1 45
Controls 38.4±14.2 40
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genes are found in scleroderma fibroblasts [33]. These results thus suggest
alterations of collagen expression at several levels (Table III).
ROLE OF CYTOKINES IN THE ACTIVATION
OF CONNECTIVE TISSUE GENE EXPRESSION
The anatomical co-localization of inflammatory cells and activated
fibroblasts in early stages of scleroderma already indicated that cytokines
released from these cells might have an important impact on the
activation. This concept was further supported by experiments showing
that supernatants from activated lymphocytes or monocytes could
regulate in vitro collagen synthesis in fibroblast cultures [34]. A better
understanding was achieved later when availability of recombinant
cytokines allowed characterization of the biologic activity of single
components of these supernatants. It turned out that Il-1 and TGF-beta1
and -beta2 are important inducers of connective tissue synthesis, whereas
IFN-gamma and TNF-alpha have down-regulating activity (for review see
[35,36]). Injection of TGF-beta into the dermis of newborn mice causes a
rapid formation of granulation tissue followed by increased deposition of
matrix proteins [37]. These events are partly due to enhanced fibroblast
migration and proliferation but also to increased collagen synthesis.
Induction of collagen and fibronectin gene expression by TGF-beta has
then been investigated in more detail on a molecular level [38–40]. Using
various collagen promoter constructs it has been demonstrated that TGF-
beta can induce collagen gene expression up to 10 times, and it was found
to act via the nuclear factor-1 (NF-1) site in the promotor region [40].
TGF-beta, either alone or in combination with epidermal growth
factor (EGF) was also shown to increase glycosaminoglycan synthesis in
fibroblasts derived from patients with systemic scleroderma [41]. In
addition, transforming growth factor-beta (TGF-beta) triggers the induc-
tion of PDGF synthesis [42], which is shown to be an important
chemoattractive agent for fibroblasts and which can induce fibroblast
proliferation [43]. PDGF gene expression has been demonstrated
immunohistologically in scleroderma skin [44]. TGF-beta was also found
to be directly involved in the development of glomerulonephritis,
inducing ECM formation [45,46].
In contrast, incubation of fibroblasts with TNF-alpha and inter-feron-
gamma diminished the steady-state levels of collagen mRNA due to
decreased gene transcription [47,48]. Although the interstitial collagens I
and III are coordinately reduced at the transcriptional level, collagen VI
production is regulated via mRNA reduction of only one alpha-chain
subunit [49]. Because IFN-gamma reduces fibroblast chemotaxis [50] and
collagen biosynthesis, it has been proposed as an antifibrotic substance
and has already been used in clinical trials for the treatment of patients
with systemic scleroderma. Similar to IFN-gamma, TNF-alpha also
reduces collagen synthesis. Moreover, it induces collagenase gene
expression and can act synergistically with IFN-gamma in inhibiting
collagen synthesis [48].
ROLE OF THE ECM IN CONTROLLING
CONNECTIVE TISSUE DEPOSITION
Most of the constituents of the ECM are large glycoproteins composed of
structurally and functionally distinct domains. There is now growing
evidence that these ECM molecules do not only act as the structural
scaffold of the tissue but also provide signals for cells, thus controlling
several cellular functions (for review see [51–53]). These include cell
migration and chemotaxis, reorganization of the cytoskeleton and cell
shape, and regulation of cellular proliferation and differentiation. Because
fibroblasts have been shown to be sensitive to various signals of the ECM,
this aspect has become an important factor in understanding the excessive
deposition of connective tissue in fibrotic diseases.
Initially fibronectin had been thought to represent the major fibroblast
attachment protein and to mediate the adhesion of these cells to collagen.
It is now clear that fibroblasts can attach directly to collagens I, III, IV, V,
and VI as well as to non-collagenous proteins like laminin [54,56]. Cell-
attachment sites have been mapped to distinct domains of the ECM
proteins. For example, the cell-adhesion site on collagen IV has been
localized to a polypeptide CB3, corresponding to the central portion of
the major triple helix. For collagen IV cell-adhesion activity has been
shown for the alpha2(VI) and alpha3(VI) chains, but not for the alpha3(VI)
chain [57]. For fibronectin, fibroblasts attach to the RGD-site.
The interactions of cells with ECM proteins involves specific cell
membrane proteins that belong to different families of receptor proteins,
e.g., the anchorins, cell-surface proteoglycans, and inte-grins, the integrin
family representing probably the most important ECM receptors (for
review see [58]). These are heterodimeric complexes consisting of one
alpha and one beta subunit. Each subunit has a large N-terminal
extracellular domain, a transmembrane domain, and a short C-terminal
cytoplasmic domain that can interact with the cytoskeleton. Beside cell-
cell receptors the integrin family includes receptors for fibronectin,
collagens, vitronectin, fibrinogen, von Willebrand factor, and laminin.
Thus the attachment of cells to extracellular matrix components turns out
to be a very complex process involving different domains and various
receptor molecules, which then mediate different signals from the
extracellular space to the cytoplasm and the nucleus.
Some ECM constituents have been shown to have growth factor-like
activity [59,60]. Thus, fibronectin can serve as growth factor for fibroblasts
and in addition interferes with the activity of growth stimulation by insulin
and FGF. Laminin has mitogenic activity for fibroblasts and epidermal
cells. This activity was attributed to the short-arm portion of the molecule,
which contains a large number of cysteine-rich motifs with homology to
EGF, as revealed by sequence analysis. Interestingly, sequence analysis of
thrombospondin, which has been shown to induce proliferation of smooth
muscle cells, also revealed a number of EGF-like motifs. These motifs are
present in several other ECM proteins; they probably represent spacers to
facilitate protein-protein interaction, and also they could provide
biologically active exposed loops for binding. Destruction of ECM
molecules following tissue damage in inflammation might liberate those
biologically active peptides. In addition, several growth factors, e.g.,
PDGF, FGF, and TGF-beta, have been found to have a high affinity for
ECM constituents, and the matrix is therefore thought to be a reservoir for
these factors that could be released following injury and lead to activation
and enhanced proliferation of certain fibroblastic cell populations [61].
Several of these matrix domains not only promote fibroblast adhesion
and proliferation but may also act as chemotactic factors. Chemotactic
activity has been shown for collagens I, II, and III, and their degradation
products, as well as for the RGD cell-attachment site of fibronectin [62].
This suggests that via several mediator functions ECM constituents can
play an important role in controlling the accumulation of fibroblastic cells
in an injured area following acute or chronic inflammatory processes.
As mentioned above, interstitial collagens are synthesized in a
precursor form and contain two large procollagen peptides at both ends
of the molecule that are cleaved off in the extracellular space. Both
peptides have been shown to act as feed-back inhibitors and by this to
regulate collagen synthesis on the transcriptional and translational level.
Although there is some divergence in the literature, some investigators
report a diminished response of scleroderma fibroblasts to these peptides,
which might explain in part the overproduction of collagen [63]. Until
now, however, it is not fully understood whether these peptides interact
with a distinct receptor on the fibroblast surface, and most of the studies
Table III. Alterations of Collagen Metabolism in
Scleroderma Fibroblasts In Vitro
Increased Normal Normal/Reduced
Transcription of
Collagen Genes
Activity of sugar
transferases
Response to
procollagen peptides
Production of
collagens I, III, VI
Degradation
Activity of PH and LH
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have been hampered by the fact that in monolayer cultures only a small
percentage of procollagen peptides is directly available to the cells.
Collagen lattices represent an in vitro system that resembles the in vivo
situation much more closely than the classic monolayer cultures [64].
When fibroblasts are seeded into three-dimensional collagen gels they
contract the gels until a dense connective tissue matrix is formed. Due to
the interaction with the ECM, fibroblasts change their morphology; they
become elongated and bipolar and display several filopodia at both cell
poles. This process is accompanied by a reorganization of the intracellular
cytoskeleton. In addition, the contact of fibroblasts with the surrounding
collagen results in a specific modulation of several fibroblast functions;
this includes protein synthesis in general but most prominent is a strong
reduction of collagen production [65,66]. This is related to decreased
synthesis and is accompanied by a simultaneous reduction of collagen-
specific mRNA levels. A comparable reduction was noted for the
interstitial collagens I and III, whereas other components of the ECM,
e.g., collagen VI and fibronectin, were not affected. Also tubulin mRNA
levels were shown to be constant. This process was found to be
transcriptionally as well as post-transcriptionally controlled. Its mechan-
ism, however, is not yet fully understood.
Recently it has been observed that antibodies directed against the
alpha2 and the beta, subunit of integrins can inhibit collagen gel
contraction by fibroblasts, indicating that this integrin is involved in
modulating cell-collagen contact [67]. When scleroderma fibroblasts are
seeded into three-dimensional collagen lattices, the rate and extent of
contraction is similar to controls; however, several cell strains from
scleroderma patients did not reveal down regulation of collagen synthesis
as observed for control cells. As reported for most in vitro studies using
scleroderma fibroblasts, there was a certain heterogeneity, and at least
half of the cell strains studied did not differ from controls. This can
probably be explained by the selection procedure in establishing these
cell cultures (for review see [68]).
Several attempts have therefore been made to compare receptor
molecules on the surface of scleroderma fibroblasts with those on control
cells, because alterations of these structures could result in disturbed
mediation of signals from the surrounding matrix to the fibroblasts.
Preliminary evidence is available that the alpha2 integrin subunit is
expressed in a reduced amount in scleroderma fibroblasts. It, remains unclear,
whether this might reflect an activated state of fibroblasts or whether the
reduction is causally related to the inability of the cells to adjust their collagen
biosynthesis accurately to the amount of surrounding ECM molecules.
CONCLUSIONS
Development of fibrosis in systemic scleroderma is the result of a complex
process, depending mainly on the interaction of cells with cytokines and
the ECM (Fig 3). An initial activation of connective-tissue synthesis in
fibroblasts is probably mediated by cytokines released from inflammatory
cells. TGF-betat and/or TGF-beta2 are most likely involved. Activation
results in an overproduction of collagens, controlled on a transcriptional
level. However, the cells remain activated even after inflammatory
infiltrates have disappeared. This phenomenon could be explained by the
selection of a certain population of fibroblasts or by a persistent alteration
of their phenotype. Definite evidence for both hypotheses has not yet
been presented, and it remains to be seen whether the initial activation as
a reaction to any tissue injury might be associated with a defective down
regulation of connective-tissue production in scleroderma patients
involving the receptor mediated interaction of the fibroblasts with the
surrounding extracellular matrix.
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